Lataa...
Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients
Emerging treatment options for hemophilia, including gene therapy, modified factor products, antibody‐based products, and other nonreplacement therapies, are in development or on their way to marketing authorization. For proof of efficacy, annual bleeding rates (ABRs) have become an increasingly imp...
Tallennettuna:
| Julkaisussa: | Clin Transl Sci |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7719362/ https://ncbi.nlm.nih.gov/pubmed/32472976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12794 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|